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Our previous studies (Hashem et al., 2006; Kapila, 2009; Naqvi et al., 2005) have 
shown that the fibrocartilaginous temporomandibular joint (TMJ) disc and pubic sym-
physis respond to relaxin by upregulation of MMPs and loss of key matrix molecules. 
These responses to relaxin are enhanced by estrogen, and are also modulated by estro-
gen alone. Since these fibrocartilaginous tissue are heterogeneous containing fibroblastic, 
chondrocytic and intermediate cell types, the responses of specific cell types to relaxin are 
not known. Also the direct effect of specific MMPs induced by relaxin to the loss carti-
lage matrix in vivo has not been demonstrated. Our purpose was to (1) characterize cell 
type-specific response(s) to relaxin and estrogen; (2) identify the relaxin receptor and 
downstream signaling involved in relaxin’s induction of specific MMPs; (3) develop a 
mouse model for in vivo manipulation of hormones; and (4) identify the contribution of 
each of these hormones and the MMPs they regulate to in vivo matrix loss. 
Two each of fibroblastic and chondrocytic female mouse TMJ disc cell clones 
immortalized by human telomerase reverse transcriptase were isolated and charac-
terized on the basis of phenotype, growth curves, and fibroblastic and chondroctytic 
markers, respectively. Chondrocytic cell clones had higher mRNA and protein expres-
sion levels of cartilage oligomeric matrix protein (COMP), collagen X, total collagen, 
collagen II, and collagen II/collagen I mRNA ratios relative to fibroblastic cell clones. 
Fibroblastic cell clones had higher mRNA and protein expression levels of vimentin 
and fibroblastic specific protein 1 (FSP1) than the chondrocytic clones. The fibroblastic 
cell clones expressed higher levels of relaxin receptors RXFP1 (>6) and RXFP2 (>9) 
while chondroctyic cell clones had higher level of estrogen receptor, ESR2 (>4.5) com-
pared to their counterparts. Consequently the fibroblastic cells showed greater upreg-
ulation of MMP-9 (>2.5) and -13 (>9) and relaxin receptors (>2) by relaxin than the 
chondrocytic cell clones, while the reverse was true for cellular responses to estrogen. 
Next using gene overexpression and suppression strategies we found that RXFP1 
but not RXFP2 is involved in the upregulation of MMP-9 and -13 in primary TMJ 
fibrocartilaginous cells (Fig. 1). Studies using chemical inhibitors and siRNAs to sign-
aling molecules revealed that relaxin induces MMP-9 via PI3K, Akt, ERK and PKC-ζ 
and the transcription factors Elk-1, c-fos and to a lesser extent NF-κB (Ahmed et al., 
2012). MMP-9 promoter-luciferase experiments demonstrated the involvement of the 
elements responsive to these transcription factors, namely Ets/Pea3, AP-1 and NF-κB, 
respectively, in relaxin’s modulation of MMP-9 (Fig. 2).
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We next assessed the contribution of relaxin-induced MMP-9 to matrix loss in vivo. 
One week following bilateral ovariectomies in 12 week-old female C57BL/6 WT or 
MMP-9 null mice, osmotic pumps containing PBS or relaxin or estrogen or a com-
bination of these hormones were implanted subcutaneously. Six days later, the mice 
were euthanized, blood was collected and TMJ discs retrieved. The discs were ana-
lyzed for collagen, glycosaminoglycan, and MMPs, while the serum was assayed for 
the hormones. The administered doses of the hormones resulted in systemic hormone 
concentrations similar to those in cycling women. In vivo administration of relaxin 
and/or estrogen contributed to the upregulation of MMP-9 and -13 concomitant with 
the loss of matrices from disc in WT mice. Unexpectedly, treatment of MMP-9 null 
mice with estrogen or relaxin also resulted in loss of disc collagen and glycosamino-
glycan to a similar extent as that in WT mice. This finding could be explained by our 
observation that relaxin and estrogen caused significantly greater induction of MMP-
13 in MMP-9 null vs. WT mice, suggesting that MMP-13 may be compensating for 
the absence of MMP-9 in relaxin-mediated matrix loss. 
The findings demonstrate that relaxin and estrogen enhance matrix loss in the 
TMJ disc concomitant with the induction of their respective receptors, MMP-9 and 
MMP-13, which are cell-type specific responses. Also the similarities between WT and 
Figure 1. RXFP1 but not RXFP2 is involved in relaxin’s induction of MMPs in TMJ fibrochondrocytes. A and B: 
Untransfected cells or cells transiently transfected with pcDNA vector, or RXFP1 or RXFP2 cDNA constructs 
were cultured in the absence or presence of relaxin. Cell-conditioned medium was collected after 48 hours 
and assayed by gelatin substrate zymography. Relaxin induced MMP-9 and -13. This response to relaxin was 
enhanced in RXFP1 but not RXFP2 cDNA transfected cells. C and D: Untransfected cells or cells transiently 
transfected with scrambled siRNA or siRNA to RXFP1 or RXFP2 were cultured in the absence or presence of 
relaxin for 48 hours. Cell-conditioned medium assayed by gelatin substrate zymography showed that relax-
in’s induction of MMP-9 and -13 was inhibited in RXFP1 but not RXFP2 siRNA transfected cells.
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MMP-9 null mice in the loss of matrix molecules on treatment with estrogen and/or 
relaxin suggest that both MMP-9 and MMP-13 may act together in contributing to tis-
sue turnover, or mediators other than MMPs may be involved in the enhanced matrix 
turnover mediated by these hormones. 
Acknowledgment
This work was supported by NIH/NIDCR RO1DE018455.
References 
Ahmed N., Wang W., Nair R., Kapila S. (2012) Relaxin induces matrix-metalloprotein-
ases-9 and -13 via RXFP1: Induction of MMP-9 involves the PI3K, ERK, Akt and 
PKC-ζ pathways. Mol Cell Endocrinology. 363: 46-61.
Hashem G., Zhang Q., Hayami T., Chen J., Wang W., Kapila S. (2006) Relaxin and 
Figure 2. The induction of MMP-9 by relaxin in TMJ fibrochondrocytes requires NF-κB, Ets/Pea3 and AP-1 
response elements in the human MMP-9 promoter. A: Human MMP-9 promoter luciferase construct utilized 
showing response key elements. B: Cells transfected with control vector or vector containing wild type or 
one of seven MMP-9 promoter-luciferase constructs each containing a deleted response element were cul-
tured in the absence or presence of relaxin for 6 hours. Cells were lysed and assayed for luciferase and b-ga-
lactosidase; the latter was used for standardizing the luciferase activity. Deletion of NF-κB, Ets/Pea3 and AP-1 
response elements diminished the baseline activation as well as relaxin’s induction of the human MMP-9 
promoter. The results shown represent means (+SE) of three independent experiments.
65Mechanisms for Relaxin’s Modulation of MMPs and Matrix Loss in Fibrocartilages
beta-estradiol modulate targeted matrix degradation in specific synovial joint 
fibrocartilages: progesterone prevents matrix loss, Arthritis Res Ther. 8, R98:1-9. 
Kapila S., Wang W., Uston K. (2009) Matrix metalloproteinase induction by relaxin 
causes cartilage matrix degradation in target synovial joints, Ann N Y Acad Sci. 
1160, 322-8.
Naqvi T., Duong T.T., Hashem G., Shiga M., Zhang Q., Kapila S. (2005) Relaxin’s induc-
tion of metalloproteinases is associated with the loss of collagen and glycosaminogly-
cans in synovial joint fibrocartilaginous explants, Arthritis Res Ther. 7, R1-11.
